Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDXX IDEXX Laboratories	$546.31 +0.7%	$510.63	$356.14 ▼ $548.54	$43.99B	1.54	645,880 shs	339,027 shs
MRK Merck & Co., Inc.	$80.97 -1.7%	$79.20	$73.31 ▼ $129.93	$203.22B	0.39	13.26 million shs	7.73 million shs
PFE Pfizer	$25.45 +0.5%	$23.72	$20.92 ▼ $31.54	$144.29B	0.58	41.63 million shs	27.10 million shs
ZTS Zoetis	$159.19 +0.1%	$161.16	$139.70 ▼ $200.33	$70.87B	0.91	2.57 million shs	1.38 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDXX IDEXX Laboratories	0.00%	+2.82%	+4.09%	+38.75%	+14.41%
MRK Merck & Co., Inc.	0.00%	+2.58%	+3.44%	-0.63%	-35.66%
PFE Pfizer	0.00%	+5.16%	+8.65%	+10.68%	-8.04%
ZTS Zoetis	0.00%	+1.94%	-5.62%	+4.90%	-9.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IDXX IDEXX Laboratories	3.8599 of 5 stars	1.4	4.0	0.0	3.7	3.5	2.5	1.3
MRK Merck & Co., Inc.	4.9962 of 5 stars	3.2	3.0	5.0	4.2	3.0	2.5	3.8
PFE Pfizer	4.9764 of 5 stars	3.2	3.0	4.2	4.5	2.8	1.7	3.1
ZTS Zoetis	4.8379 of 5 stars	3.5	5.0	4.2	0.4	3.1	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IDXX IDEXX Laboratories	2.80	Moderate Buy	$558.11	2.16% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	34.85% Upside
PFE Pfizer	2.45	Hold	$28.55	12.20% Upside
ZTS Zoetis	3.00	Buy	$212.13	33.25% Upside

Current Analyst Ratings Breakdown

Latest ZTS, IDXX, MRK, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$510.00 ➝ $540.00
7/1/2025	IDXX IDEXX Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$625.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/11/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $580.00
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/19/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$460.00 ➝ $510.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/12/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$205.00 ➝ $210.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IDXX IDEXX Laboratories	$3.90B	11.27	$12.41 per share	44.01	$19.48 per share	28.04
MRK Merck & Co., Inc.	$64.17B	3.17	$9.47 per share	8.55	$18.33 per share	4.42
PFE Pfizer	$63.63B	2.27	$4.37 per share	5.82	$15.62 per share	1.63
ZTS Zoetis	$9.26B	7.66	$7.07 per share	22.51	$10.57 per share	15.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IDXX IDEXX Laboratories	$887.87M	$10.82	50.49	40.23	3.99	22.76%	57.35%	26.97%	8/4/2025 (Confirmed)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.79	8.18	0.84	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	18.44	8.40	0.92	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.58	23.58	2.64	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest ZTS, IDXX, MRK, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	$2.96	+$0.03	$2.96	$998.25 million	$998.43 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	4.00%	N/A	47.16%	14 Years
PFE Pfizer	$1.72	6.76%	N/A	124.64%	16 Years
ZTS Zoetis	$2.00	1.26%	N/A	35.91%	14 Years

Latest ZTS, IDXX, MRK, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IDXX IDEXX Laboratories	0.31	1.16	0.81
MRK Merck & Co., Inc.	0.69	1.41	1.16
PFE Pfizer	0.64	1.26	0.96
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IDXX IDEXX Laboratories	87.84%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
IDXX IDEXX Laboratories	0.98%
MRK Merck & Co., Inc.	0.13%
PFE Pfizer	0.06%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IDXX IDEXX Laboratories	11,000	80.42 million	79.63 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

ZTS, IDXX, MRK, and PFE Headlines

Recent News About These Companies

Novare Capital Management LLC Has $15.75 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 5 at 8:51 AM | marketbeat.com

Bank of New York Mellon Corp Decreases Stock Position in Zoetis Inc. (NYSE:ZTS)

July 5 at 8:26 AM | marketbeat.com

VELA Investment Management LLC Buys 3,823 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 8:09 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Impax Asset Management Group plc

July 5 at 6:53 AM | marketbeat.com

IFM Investors Pty Ltd Buys 8,570 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 6:28 AM | marketbeat.com

Calamos Advisors LLC Sells 87,156 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 5:57 AM | marketbeat.com

Kintegral Advisory LLC Sells 9,036 Shares of Zoetis Inc. (NYSE:ZTS)

July 4 at 8:38 AM | marketbeat.com

Hartline Investment Corp Trims Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 7:45 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Fisher Funds Management LTD

July 4 at 7:28 AM | marketbeat.com

Calamos Wealth Management LLC Has $14.11 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 4 at 7:18 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Position Increased by Aviance Capital Partners LLC

July 4 at 7:02 AM | marketbeat.com

Aurora Private Wealth Inc. Acquires New Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 6:35 AM | marketbeat.com

Teacher Retirement System of Texas Decreases Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 5:34 AM | marketbeat.com

Is Zoetis Gaining or Losing Market Support?

July 4 at 5:30 AM | benzinga.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by First Horizon Advisors Inc.

July 4 at 5:26 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Palisade Capital Management LP

July 3 at 9:47 AM | marketbeat.com

Summit Place Financial Advisors LLC Buys 1,755 Shares of Zoetis Inc. (NYSE:ZTS)

July 3 at 9:02 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Principal Financial Group Inc.

July 3 at 8:45 AM | marketbeat.com

ZTS | Zoetis Inc. Annual Income Statement | MarketWatch

July 3 at 8:27 AM | marketwatch.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Tandem Investment Advisors Inc.

July 3 at 8:20 AM | marketbeat.com

Keybank National Association OH Sells 17,219 Shares of Zoetis Inc. (NYSE:ZTS)

July 3 at 5:37 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS, IDXX, MRK, and PFE Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

$546.31 +3.60 (+0.66%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$546.31 0.00 (0.00%)

As of 07/3/2025 04:04 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Merck & Co., Inc. NYSE:MRK

$80.97 -1.42 (-1.72%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$80.99 +0.02 (+0.02%)

As of 07/3/2025 04:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.44 +0.13 (+0.49%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$25.42 -0.03 (-0.11%)

As of 07/3/2025 05:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$159.19 +0.11 (+0.07%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$159.19 0.00 (0.00%)

As of 07/3/2025 04:51 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time